Patterns of Care and Outcomes of Low-Lying Adenocarcinoma and Squamous Cell Carcinoma of the Rectum.
Neoadjuvant chemoradiation
Rectal adenocarcinoma
Rectal carcinoma
Rectal squamous cell carcinoma
Journal
Journal of gastrointestinal cancer
ISSN: 1941-6636
Titre abrégé: J Gastrointest Cancer
Pays: United States
ID NLM: 101479627
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
accepted:
08
11
2020
pubmed:
20
11
2020
medline:
26
3
2022
entrez:
19
11
2020
Statut:
ppublish
Résumé
Squamous cell carcinoma (SCC) of the rectum is a unique entity that lacks definitive guidelines regarding prognosis and treatment. This study aimed to analyze patterns of care and survival for SCC and adenocarcinoma (AC) of the rectum. This was a retrospective analysis of patients with stage I-III SCC or AC of the rectum treated from 2004 to 2016 from the National Cancer Database. The treatment groups analyzed were surgery alone (S), chemoradiation followed by surgery (CRT + S), surgery followed by chemoradiation (S + CRT), and definitive chemoradiation (CRT). Patient- and clinical-related factors were compared. Overall survival was assessed with the Kaplan-Meier method and Cox proportional regression models. Of the patients studied, 21,587 (97.1%) were AC and 640 (2.9%) were SCC. Among patients with AC, most (n = 8549, 59.4%) received chemoradiation followed by surgery; those with SCC (n = 305, 66.4%) received definitive chemoradiation. Among patients who received surgery, the majority (69.2%) with AC histology had a low anterior resection while the majority (52.1%) of SCC had an abdominoperineal resection. Five-year overall survival of AC versus SCC in the entire cohort was 61.6% versus 56.1%, respectively (p < 0.001). On multivariable analysis for AC, CRT + S (HR 0.61, p < 0.001), or S + CRT (HR 0.67, p < 0.001) had improved survival compared to S alone while those who had definitive CRT (HR 1.55, p < 0.001) had worse survival. SCC of the rectum tends to be treated like anal cancers with definitive chemoradiation, with similar survival to historical reports of anal cancer. AC of the rectum is most commonly treated under the rectal cancer paradigm.
Identifiants
pubmed: 33211265
doi: 10.1007/s12029-020-00552-3
pii: 10.1007/s12029-020-00552-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
105-112Informations de copyright
© 2020. Springer Science+Business Media, LLC, part of Springer Nature.
Références
Dutta SW, Alonso CE, Waddle MR, Khandelwal SR, Janowski EM, Trifiletti DM. Squamous cell carcinoma of the rectum: practice trends and patient survival. Cancer Med. 2018;7(12):6093–103.
doi: 10.1002/cam4.1893
Guerra GR, Kong CH, Warrier SK, Lynch AC, Heriot AG, Ngan SY. Primary squamous cell carcinoma of the rectum: an update and implications for treatment. World J Gastrointest Surg. 2016;8(3):252–65.
doi: 10.4240/wjgs.v8.i3.252
Peron J, et al. Nonoperative management of squamous-cell carcinoma of the rectum. Dis Colon Rectum. 2015;58(1):60–4.
doi: 10.1097/DCR.0000000000000218
Musio D, de Felice F, Manfrida S, Balducci M, Meldolesi E, Gravina GL, et al. Squamous cell carcinoma of the rectum: the treatment paradigm. Eur J Surg Oncol. 2015;41(8):1054–8.
doi: 10.1016/j.ejso.2015.03.239
Dyson T, Draganov PV. Squamous cell cancer of the rectum. World J Gastroenterol. 2009;15(35):4380–6.
doi: 10.3748/wjg.15.4380
Kommalapati A, Tella SH, Yadav S, Goyal G, Hallemeier C, Durgin L, et al. Survival and prognostic factors in patients with rectal squamous cell carcinoma. Eur J Surg Oncol. 2020;46:1111–7.
doi: 10.1016/j.ejso.2020.02.039
Chiu MS, Verma V, Bennion NR, Bhirud AR, Li J, Charlton ME, et al. Comparison of outcomes between rectal squamous cell carcinoma and adenocarcinoma. Cancer Med. 2016;5(12):3394–402.
doi: 10.1002/cam4.927
Nigro ND, Vaitkevicius VK, Buroker T, Bradley GT, Considine B. Combined therapy for cancer of the anal canal. Dis Colon Rectum. 1981;24(2):73–5.
doi: 10.1007/BF02604287
Diao JD, Wu CJ, Cui HX, Bu MW, Yue D, Wang X, et al. Nomogram predicting overall survival of rectal squamous cell carcinomas patients based on the SEER database: a population-based STROBE cohort study. Medicine (Baltimore). 2019;98(46):e17916.
doi: 10.1097/MD.0000000000017916
Vezeridis MP, Herrera LO, Lopez GE, Ledesma EJ, Mittleman A. Squamous-cell carcinoma of the colon and rectum. Dis Colon Rectum. 1983;26(3):188–91.
doi: 10.1007/BF02560169
Jeong BG, Kim DY, Kim SY. Concurrent chemoradiotherapy for squamous cell carcinoma of the rectum. Hepatogastroenterology. 2013;60(123):512–6.
pubmed: 23635435
Yeh J, Hastings J, Rao A, Abbas MA. Squamous cell carcinoma of the rectum: a single institution experience. Tech Coloproctol. 2012;16(5):349–54.
doi: 10.1007/s10151-012-0848-z
Nahas CS, et al. Squamous-cell carcinoma of the rectum: a rare but curable tumor. Dis Colon Rectum. 2007;50(9):1393–400.
doi: 10.1007/s10350-007-0256-z
Clark J, Cleator S, Goldin R, Lowdell C, Darzi A, Ziprin P. Treatment of primary rectal squamous cell carcinoma by primary chemoradiotherapy: should surgery still be considered a standard of care? Eur J Cancer. 2008;44(16):2340–3.
doi: 10.1016/j.ejca.2008.07.004
Sturgeon JD, Crane CH, Krishnan S, Minsky BD, Skibber JM, Rodriguez-Bigas MA, et al. Definitive chemoradiation for squamous cell carcinoma of the rectum. Am J Clin Oncol. 2017;40(2):163–6.
doi: 10.1097/COC.0000000000000126